Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct to Support Third Clinical Program
Actinium Pharmaceuticals, Inc.(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225.
View full press release